{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:23:14Z","timestamp":1783624994678,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic obstructive pulmonary disease (COPD) frequently coexists with other chronic diseases, namely comorbidities. They negatively impact prognosis, exacerbations and quality of life in COPD patients. However, no studies have been performed to explore the impact of these comorbidities on COPD clinical control criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Research question<\/jats:title>\n                <jats:p>Determine the relationship between individualized comorbidities and COPD clinical control criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Study design and methods<\/jats:title>\n                <jats:p>Observational, multicenter, cross-sectional study performed in Spain involving 4801 patients with severe COPD (&lt;\u200950 predicted forced expiratory volume in the first second [FEV<jats:sub>1<\/jats:sub>%]). Clinical control criteria were defined by the combination of COPD assessment test (CAT) scores (\u226416 vs \u226517) and exacerbations in the previous three months (none vs \u22651). Binary logistic regression adjusted by age and FEV<jats:sub>1<\/jats:sub>% was performed to identify comorbidities potentially associated with the lack of control of COPD. Secondary endpoints were the relationship between individualized comorbidities with COPD assessment test and exacerbations within the last three months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Most frequent comorbidities were arterial hypertension (51.2%), dyslipidemia (36.0%), diabetes (24.9%), obstructive sleep apnea-hypopnea syndrome (14.9%), anxiety (14.1%), heart failure (11.6%), depression (11.8%), atrial fibrillation (11.5%), peripheral arterial vascular disease (10.4%) and ischemic heart disease (10.1%). After age and FEV<jats:sub>1<\/jats:sub>% adjustment, comorbidities related to lack of clinical control were cardiovascular diseases (heart failure, peripheral vascular disease and atrial fibrillation; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), psychologic disorders (anxiety and depression; all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), metabolic diseases (diabetes, arterial hypertension and abdominal obesity; all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), sleep disorders (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), anemia (<jats:italic>p<\/jats:italic>\u2009=\u20090.015) and gastroesophageal reflux (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). These comorbidities were also related to previous exacerbations and COPD assessment test scores.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Interpretation<\/jats:title>\n                <jats:p>Comorbidities are frequent in patients with severe COPD, negatively impacting COPD clinical control criteria. They are related to health-related quality of life measured by the COPD assessment test. Our results suggest that comorbidities should be investigated and treated in these patients to improve their clinical control.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Take-home points<\/jats:title>\n                <jats:p><jats:bold>Study question:<\/jats:bold> What is the impact of comorbidities on COPD clinical control criteria?<\/jats:p>\n                <jats:p><jats:bold>Results:<\/jats:bold> Among 4801 patients with severe COPD (27.5% controlled and 72.5% uncontrolled), after adjustment by age and FEV<jats:sub>1<\/jats:sub>%, comorbidities related to lack of clinical control were cardiovascular diseases (heart failure, peripheral vascular disease and atrial fibrillation; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), psychologic disorders (anxiety and depression; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), metabolic diseases (diabetes, arterial hypertension and abdominal obesity; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), obstructive sleep apnea-hypopnea syndrome (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), anaemia (<jats:italic>p<\/jats:italic>\u2009=\u20090.015) and gastroesophageal reflux (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), which were related to previous exacerbations and COPD assessment test scores.<\/jats:p>\n                <jats:p><jats:bold>Interpretation:<\/jats:bold> Comorbidities are related to health-related quality of life measured by the COPD assessment test scores and history of exacerbations in the previous three months.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-023-02758-0","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T09:02:23Z","timestamp":1704186143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Impact of comorbidities in COPD clinical control criteria. The CLAVE study"],"prefix":"10.1186","volume":"24","author":[{"given":"Pere","family":"Almagro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Soler-Catalu\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Huerta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Gonz\u00e1lez-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja G.","family":"Cos\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the CLAVE Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"key":"2758_CR1","volume-title":"Global Initiative for Chronic Obstructive Lung Disease","year":"2021","unstructured":"GOLD Reports. Global Initiative for Chronic Obstructive Lung Disease. GOLD; 2021. https:\/\/goldcopd.org\/2021-gold-reports\/. Accessed 7 Dec 2020."},{"key":"2758_CR2","doi-asserted-by":"publisher","unstructured":"Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health. 2015;5(2) https:\/\/doi.org\/10.7189\/JOGH.05-020415.","DOI":"10.7189\/JOGH.05-020415"},{"issue":"10053","key":"2758_CR3","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/S0140-6736(16)31012-1","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","unstructured":"GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459\u2013544.","journal-title":"Lancet"},{"issue":"13","key":"2758_CR4","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMra1900500","volume":"381","author":"BR Celli","year":"2019","unstructured":"Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257\u201366. https:\/\/doi.org\/10.1056\/NEJMra1900500.","journal-title":"N Engl J Med"},{"issue":"2","key":"2758_CR5","doi-asserted-by":"publisher","first-page":"T159","DOI":"10.1016\/j.arbres.2021.05.033","volume":"58","author":"JJ Soler-Catalu\u00f1a","year":"2022","unstructured":"Soler-Catalu\u00f1a JJ, Pi\u00f1era P, Trigueros JA, et al. Spanish COPD guidelines (GesEPOC) 2021 update. Diagnosis and treatment of COPD exacerbation syndrome. Arch Bronconeumol. 2022;58(2):T159\u201370. https:\/\/doi.org\/10.1016\/j.arbres.2021.05.033.","journal-title":"Arch Bronconeumol"},{"key":"2758_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/COPD.S285385","volume":"16","author":"JJ Soler-Catalu\u00f1a","year":"2021","unstructured":"Soler-Catalu\u00f1a JJ, Almagro P, Huerta A, et al. Clinical control criteria to determine disease control in patients with severe COPD: the CLAVE study. Int J Chron Obstruct Pulmon Dis. 2021;16:137\u201346. https:\/\/doi.org\/10.2147\/COPD.S285385.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"11","key":"2758_CR7","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/resp.13811","volume":"25","author":"M Miravitlles","year":"2020","unstructured":"Miravitlles M, Sliwinski P, Rhee CK, et al. Predictive value of control of COPD for risk of exacerbations: an international, prospective study. Respirol. 2020;25(11):1136\u201343. https:\/\/doi.org\/10.1111\/resp.13811.","journal-title":"Respirol"},{"issue":"1","key":"2758_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12931-021-01633-y","volume":"22","author":"M Calle Rubio","year":"2021","unstructured":"Calle Rubio M, Rodriguez Hermosa JL, de Torres JP, et al. COPD clinical control: predictors and long-term follow-up of the CHAIN cohort. Respir Res. 2021;22(1):36. https:\/\/doi.org\/10.1186\/s12931-021-01633-y.","journal-title":"Respir Res"},{"key":"2758_CR9","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.2147\/COPD.S178149","volume":"13","author":"JJ Soler-Catalu\u00f1a","year":"2018","unstructured":"Soler-Catalu\u00f1a JJ, Marzo M, Catal\u00e1n P, Miralles C, Alcazar B, Miravitlles M. Validation of clinical control in COPD as a new tool for optimizing treatment. Int J Chron Obstruct Pulmon Dis. 2018;13:3719\u201331. https:\/\/doi.org\/10.2147\/COPD.S178149.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"5","key":"2758_CR10","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/J.CHEST.2019.11.004","volume":"157","author":"JJ Soler-Catalu\u00f1a","year":"2020","unstructured":"Soler-Catalu\u00f1a JJ, Alc\u00e1zar B, Marzo M, P\u00e9rez J, Miravitlles M. Evaluation of changes in control status in COPD: an opportunity for early intervention. Chest. 2020;157(5):1138\u201346. https:\/\/doi.org\/10.1016\/J.CHEST.2019.11.004.","journal-title":"Chest"},{"key":"2758_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1465-9921-15-3","volume":"15","author":"C Casanova","year":"2014","unstructured":"Casanova C, Marin JM, Martinez-Gonzalez C, et al. New GOLD classification: longitudinal data on group assignment. Respir Res. 2014;15:3. https:\/\/doi.org\/10.1186\/1465-9921-15-3.","journal-title":"Respir Res"},{"issue":"2","key":"2758_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1378\/CHEST.15-1752","volume":"149","author":"M Karloh","year":"2016","unstructured":"Karloh M, Mayer AF, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E. The COPD assessment test: what do we know so far?: a systematic review and meta-analysis about clinical outcomes prediction and classification of patients into GOLD stages. Chest. 2016;149(2):413\u201325. https:\/\/doi.org\/10.1378\/CHEST.15-1752.","journal-title":"Chest"},{"key":"2758_CR13","doi-asserted-by":"publisher","unstructured":"Sadatsafavi M, McCormack J, Petkau J, Lynd LD, Lee TY, Sin DD. Should the number of acute exacerbations in the previous year be used to guide treatments in COPD? Eur Respir J. 2021;57(2) https:\/\/doi.org\/10.1183\/13993003.02122-2020.","DOI":"10.1183\/13993003.02122-2020"},{"issue":"5","key":"2758_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/15412555.2017.1350154","volume":"14","author":"A Nibber","year":"2017","unstructured":"Nibber A, Chisholm A, Soler-Catalu\u00f1a JJ, Alcazar B, Price D, Miravitlles M. Validating the concept of COPD control: a real-world cohort study from the United Kingdom. COPD. 2017;14(5):504\u201312. https:\/\/doi.org\/10.1080\/15412555.2017.1350154.","journal-title":"COPD"},{"key":"2758_CR15","doi-asserted-by":"publisher","unstructured":"Miravitlles M, Sliwinski P, Rhee CK, et al. Changes in control status of COPD over time and their consequences: a prospective international study. Arch Bronconeumol. 2021;57(2) https:\/\/doi.org\/10.1016\/J.ARBRES.2020.06.003.","DOI":"10.1016\/J.ARBRES.2020.06.003"},{"key":"2758_CR16","doi-asserted-by":"publisher","unstructured":"Burke H, Wilkinson TMA. Unravelling the mechanisms driving multimorbidity in COPD to develop holistic approaches to patient-centred care. Eur Respir Rev. 2021;30(160) https:\/\/doi.org\/10.1183\/16000617.0041-2021.","DOI":"10.1183\/16000617.0041-2021"},{"issue":"1","key":"2758_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1093\/ageing\/afs100","volume":"42","author":"LD Hughes","year":"2013","unstructured":"Hughes LD, McMurdo MET, Guthrie B. Guidelines for people not for diseases: the challenges of applying U.K. clinical guidelines to people with multimorbidity. Age Ageing. 2013;42(1):62\u20139. https:\/\/doi.org\/10.1093\/ageing\/afs100.","journal-title":"Age Ageing"},{"key":"2758_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.2147\/COPD.S49621","volume":"9","author":"MC Smith","year":"2014","unstructured":"Smith MC, Wrobel JP. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J COPD. 2014;9:871\u201388. https:\/\/doi.org\/10.2147\/COPD.S49621.","journal-title":"Int J COPD"},{"issue":"7","key":"2758_CR19","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1164\/rccm.201209-1665OC","volume":"187","author":"LEGWGW Vanfleteren","year":"2013","unstructured":"Vanfleteren LEGWGW, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728\u201335. https:\/\/doi.org\/10.1164\/rccm.201209-1665OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"2758_CR20","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1378\/chest.11-2413","volume":"142","author":"P Almagro","year":"2012","unstructured":"Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en servicios de medicina interna (ESMI) study. Chest. 2012;142(5):1126\u201333. https:\/\/doi.org\/10.1378\/chest.11-2413.","journal-title":"Chest"},{"issue":"2","key":"2758_CR21","doi-asserted-by":"publisher","first-page":"e0193143","DOI":"10.1371\/journal.pone.0193143","volume":"13","author":"MJ Divo","year":"2018","unstructured":"Divo MJ, Celli BR, Poblador-Plou B, et al. Chronic obstructive pulmonary disease (COPD) as a disease of early aging: evidence from the EpiChron cohort. PLoS One. 2018;13(2):e0193143. https:\/\/doi.org\/10.1371\/journal.pone.0193143.","journal-title":"PLoS One"},{"issue":"1","key":"2758_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1183\/09031936.00114307","volume":"31","author":"LM Fabbri","year":"2008","unstructured":"Fabbri LM, Luppi F, Begh\u00e9 B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204\u201312. https:\/\/doi.org\/10.1183\/09031936.00114307.","journal-title":"Eur Respir J"},{"issue":"3","key":"2758_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline LN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648\u201354. https:\/\/doi.org\/10.1183\/09031936.00102509.","journal-title":"Eur Respir J"},{"issue":"5","key":"2758_CR24","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"5","key":"2758_CR25","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1378\/chest.11-2413","volume":"142","author":"P Almagro","year":"2012","unstructured":"Almagro P, Cabrera FJ, Diez J, et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD. Chest. 2012;142(5):1126\u201333. https:\/\/doi.org\/10.1378\/chest.11-2413.","journal-title":"Chest"},{"key":"2758_CR26","doi-asserted-by":"publisher","unstructured":"Raherison C, Ouaalaya EH, Bernady A, et al. Comorbidities and COPD severity in a clinic-based cohort. BMC Pulm Med. 2018;18(1) https:\/\/doi.org\/10.1186\/S12890-018-0684-7.","DOI":"10.1186\/S12890-018-0684-7"},{"issue":"8","key":"2758_CR27","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4187\/RESPCARE.07136","volume":"65","author":"NS Hansen","year":"2020","unstructured":"Hansen NS, \u00c4ngquist L, Lange P, Jacobsen R. Comorbidity clusters and healthcare use in individuals with COPD. Respir Care. 2020;65(8):1120\u20137. https:\/\/doi.org\/10.4187\/RESPCARE.07136.","journal-title":"Respir Care"},{"issue":"2","key":"2758_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1164\/rccm.201201-0034OC","volume":"186","author":"M Divo","year":"2012","unstructured":"Divo M, Cote C, De Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155\u201361. https:\/\/doi.org\/10.1164\/rccm.201201-0034OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2758_CR29","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.3390\/nu13082811","volume":"13","author":"C Pelaia","year":"2021","unstructured":"Pelaia C, Pastori D, Armentaro G, et al. Predictors of renal function worsening in patients with chronic obstructive pulmonary disease (COPD): a multicenter observational study. Nutrients. 2021;13(8):2811. https:\/\/doi.org\/10.3390\/nu13082811.","journal-title":"Nutrients"},{"issue":"14","key":"2758_CR30","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/J.JACC.2010.05.034","volume":"56","author":"S Mottillo","year":"2010","unstructured":"Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol. 2010;56(14):1113\u201332. https:\/\/doi.org\/10.1016\/J.JACC.2010.05.034.","journal-title":"J Am Coll Cardiol"},{"issue":"7121","key":"2758_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/NATURE05488","volume":"444","author":"JP Despr\u00e9s","year":"2006","unstructured":"Despr\u00e9s JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881\u20137. https:\/\/doi.org\/10.1038\/NATURE05488.","journal-title":"Nature"},{"issue":"3","key":"2758_CR32","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3109\/15412555.2016.1140732","volume":"13","author":"N Cebron Lipovec","year":"2016","unstructured":"Cebron Lipovec N, Beijers RJHCG, van den Borst B, Doehner W, Lainscak M, Schols AMWJ. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. COPD. 2016;13(3):399\u2013406. https:\/\/doi.org\/10.3109\/15412555.2016.1140732.","journal-title":"COPD"},{"issue":"4","key":"2758_CR33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s11739-013-0945-7","volume":"9","author":"J Diez-Manglano","year":"2014","unstructured":"Diez-Manglano J, Barquero-Romero J, Almagro P, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med. 2014;9(4):419\u201325. https:\/\/doi.org\/10.1007\/s11739-013-0945-7.","journal-title":"Intern Emerg Med"},{"issue":"8","key":"2758_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/S2213-2600(15)00241-6","volume":"3","author":"W Chen","year":"2015","unstructured":"Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631\u20139. https:\/\/doi.org\/10.1016\/S2213-2600(15)00241-6.","journal-title":"Lancet Respir Med"},{"issue":"19","key":"2758_CR35","doi-asserted-by":"publisher","first-page":"e6836","DOI":"10.1097\/MD.0000000000006836","volume":"96","author":"HL Yin","year":"2017","unstructured":"Yin HL, Yin SQ, Lin QY, Xu Y, Xu HW, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients. Med. 2017;96(19):e6836. https:\/\/doi.org\/10.1097\/MD.0000000000006836.","journal-title":"Med"},{"issue":"19","key":"2758_CR36","doi-asserted-by":"publisher","first-page":"e6826","DOI":"10.1097\/MD.0000000000006826","volume":"96","author":"SH Kim","year":"2017","unstructured":"Kim SH, Park JH, Lee JK, Heo EY, Kim DK, Chung HS. Chronic obstructive pulmonary disease is independently associated with hypertension in men: a survey design analysis using nationwide survey data. Med. 2017;96(19):e6826. https:\/\/doi.org\/10.1097\/MD.0000000000006826.","journal-title":"Med"},{"issue":"4","key":"2758_CR37","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1183\/09031936.00012408","volume":"32","author":"DM Mannino","year":"2008","unstructured":"Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962\u20139. https:\/\/doi.org\/10.1183\/09031936.00012408.","journal-title":"Eur Respir J"},{"issue":"9","key":"2758_CR38","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.rmed.2013.05.001","volume":"107","author":"J Miller","year":"2013","unstructured":"Miller J, Edwards LD, Agust\u00ed A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013;107(9):1376\u201384. https:\/\/doi.org\/10.1016\/j.rmed.2013.05.001.","journal-title":"Respir Med"},{"key":"2758_CR39","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2147\/COPD.S238214","volume":"15","author":"P Almagro","year":"2020","unstructured":"Almagro P, Boixeda R, Diez-Manglano J, G\u00f3mez-Ant\u00fanez M, L\u00f3pez-Garc\u00eda F, Recio J. Insights into chronic obstructive pulmonary disease as critical risk factor for cardiovascular disease. Int J COPD. 2020;15:755\u201364. https:\/\/doi.org\/10.2147\/COPD.S238214.","journal-title":"Int J COPD"},{"issue":"4","key":"2758_CR40","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1378\/chest.12-2847","volume":"144","author":"H M\u00fcllerova","year":"2013","unstructured":"M\u00fcllerova H, Agusti A, Erqou S, Mapel DW. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163\u201378. https:\/\/doi.org\/10.1378\/chest.12-2847.","journal-title":"Chest"},{"issue":"2","key":"2758_CR41","doi-asserted-by":"publisher","first-page":"e13887","DOI":"10.1111\/eci.13887","volume":"53","author":"G Armentaro","year":"2023","unstructured":"Armentaro G, Pelaia C, Cassano V, et al. Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients. Eur J Clin Investig. 2023;53(2):e13887. https:\/\/doi.org\/10.1111\/eci.13887.","journal-title":"Eur J Clin Investig"},{"key":"2758_CR42","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.2147\/COPD.S145910","volume":"12","author":"H Lee","year":"2017","unstructured":"Lee H, Jhun BW, Cho J, et al. Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity. Int J COPD. 2017;12:3301\u201310. https:\/\/doi.org\/10.2147\/COPD.S145910.","journal-title":"Int J COPD"},{"issue":"8","key":"2758_CR43","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/THORAXJNL-2020-216390","volume":"76","author":"EL Axson","year":"2021","unstructured":"Axson EL, Bottle A, Cowie MR, Quint JK. Relationship between heart failure and the risk of acute exacerbation of COPD. Thorax. 2021;76(8):807\u201314. https:\/\/doi.org\/10.1136\/THORAXJNL-2020-216390.","journal-title":"Thorax"},{"issue":"2","key":"2758_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1164\/rccm.201602-0354OC","volume":"195","author":"S Houben-Wilke","year":"2017","unstructured":"Houben-Wilke S, J\u00f6rres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and systemic consequences\u2013comorbidities network study. Am J Respir Crit Care Med. 2017;195(2):189\u201397. https:\/\/doi.org\/10.1164\/rccm.201602-0354OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"2758_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1465-9921-15-13","volume":"15","author":"M Miyazaki","year":"2014","unstructured":"Miyazaki M, Nakamura H, Chubachi S, et al. Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res. 2014;15(1):1\u20138. https:\/\/doi.org\/10.1186\/1465-9921-15-13.","journal-title":"Respir Res"},{"issue":"1","key":"2758_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12890-016-0238-9\/TABLES\/4","volume":"16","author":"ME Wacker","year":"2016","unstructured":"Wacker ME, J\u00f6rres RA, Karch A, et al. Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016;16(1):1\u201311. https:\/\/doi.org\/10.1186\/S12890-016-0238-9\/TABLES\/4.","journal-title":"BMC Pulm Med"},{"key":"2758_CR47","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/J.JAD.2017.06.009","volume":"221","author":"JR Read","year":"2017","unstructured":"Read JR, Sharpe L, Modini M, Dear BF. Multimorbidity and depression: a systematic review and meta-analysis. J Affect Disord. 2017;221:36\u201346. https:\/\/doi.org\/10.1016\/J.JAD.2017.06.009.","journal-title":"J Affect Disord"},{"key":"2758_CR48","doi-asserted-by":"publisher","unstructured":"Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009;190(S7) https:\/\/doi.org\/10.5694\/J.1326-5377.2009.TB02471.X.","DOI":"10.5694\/J.1326-5377.2009.TB02471.X"},{"issue":"3","key":"2758_CR49","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1183\/09031936.05.00078504","volume":"26","author":"G Gudmundsson","year":"2005","unstructured":"Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalization in COPD: role of health status, anxiety and depression. Eur Respir J. 2005;26(3):414\u20139. https:\/\/doi.org\/10.1183\/09031936.05.00078504.","journal-title":"Eur Respir J"},{"issue":"9","key":"2758_CR50","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1164\/rccm.200804-619OC","volume":"178","author":"W Xu","year":"2008","unstructured":"Xu W, Collet JP, Shapiro S, et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med. 2008;178(9):913\u201320. https:\/\/doi.org\/10.1164\/rccm.200804-619OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"2758_CR51","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1513\/AnnalsATS.201708-687OC","volume":"15","author":"N Putcha","year":"2018","unstructured":"Putcha N, Fawzy A, Paul GG, et al. Anemia and adverse outcomes in a chronic obstructive pulmonary disease population with a high burden of comorbidities an analysis from SPIROMICS. Ann Am Thorac Soc. 2018;15(6):710\u20137. https:\/\/doi.org\/10.1513\/AnnalsATS.201708-687OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"10","key":"2758_CR52","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1111\/j.1532-5415.2012.04171.x","volume":"60","author":"SS Chang","year":"2012","unstructured":"Chang SS, Chen S, McAvay GJ, Tinetti ME. Effect of coexisting chronic obstructive pulmonary disease and cognitive impairment on health outcomes in older adults. J Am Geriatr Soc. 2012;60(10):1839\u201346. https:\/\/doi.org\/10.1111\/j.1532-5415.2012.04171.x.","journal-title":"J Am Geriatr Soc"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02758-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02758-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02758-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T21:18:16Z","timestamp":1704230296000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02758-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2758"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02758-0","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Research Ethics Committee of the Hospital Clinic of Barcelona (Spain), and procedures were performed in accordance with the Declaration of Helsinki. Informed consent was obtained from all subjects and\/or their legal guardian(s).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Pere Almagro declares he has received speaking or advisory fees, or economic aid to attend congresses from Astra-Zeneca, GSK, Novartis, Chiesi, Menarini, Boehringer-Ingelheim, Ferrer, and Rovi. Borja G Cos\u00edo declares he has received speaking or advisory fees, or economic aid to attend congresses from Astra-Zeneca, GSK, Novartis, Chiesi, Mundipharma, Menarini, Sanofi, TEVA, Boehringer-Ingelheim, and Rovi. He also reports non-financial support from Separ. Juan Jos\u00e9 Soler-Catalu\u00f1a has received speaker fees from AstraZeneca, Bial, Boehringer Ingelheim, Chiesi, GSK, Menarini, and consulting fees from Bial, Boehringer Ingelheim, Chiesi and GSK. Diego Gonz\u00e1lez-Segura is an employee of Chiesi Espa\u00f1a SAU, the sponsor of the study. The authors report no other conflicts of interest in this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}